Mupirocin: applications and production
Mupirocin is an antibiotic from monocarboxylic acid class used as antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) and can be obtained as a mixture of four pseudomonic acids by Pseudomonas fluorescens biosynthesis. Nowadays improving antibiotics occupies an important place in the pharmaceutical industry as more and more resistant microorganisms are developing. Mupirocin is used to control the MRSA outbreaks, for infections of soft tissue or skin and for nasal decolonization. Due to its wide use without prescription, the microorganism’s resistance to Mupirocin increased from up to 81%, thus becoming imperative its control or improvement. As the biotechnological production of Mupirocin has not been previously reviewed, in the present paper we summarize some consideration on the biochemical process for the production of pseudomonic acids (submerged fermentation and product recovery). Different strains of Pseudomonas, different culture medium and different conditions for the fermentation were analysed related to the antibiotics yield and the product recovery step is analysed in relation to the final purity. However, many challenges have to be overcome in order to obtain pseudomonic acid new versions with better properties related to antibacterial activity.
KeywordsAntibiotic resistance Biosynthesis Mupirocin Pseudomonic acid Separation
This work was supported by a Grant of Ministry or Research and Innovation, CNCS—UEFISCDI, Project PN III PCE 6/2017, Code PN-III-P4-ID-PCE-2016-0100, within PNCDI III.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Barta I, Tegdes A, Szell V, Szabo C, Arvai ENN, Keri W, Leonov D, Lang I, Igloy MBN, Jerkovich G, Salat J (2001) Process for the isolation of pseudomonic acid A from pseudomonic acid complex containing culture broth. Patent US 6,245,921 B1Google Scholar
- Bisschops MAT, Reijns TGP, Mathiesen A, Aassveen L (2009) Purification of mupirocin. Patent US 7,619,102 B2Google Scholar
- Curzons AD (1987) Isolation of pseudomonic acid. United States Patent 4,639,534Google Scholar
- Gulyas E, Balogh G, Erdei J, Seress P (2008). pH controlled fermentation process for pseudomonic acid production. US Patent US 7439,045 B2Google Scholar
- Kufrin G (2008) Finding the optimum composition of nutrient medium needed for the growth of Pseudomonas fluorescens and for the biosynthesis of mupirocin. Dissertation, University of ZagrebGoogle Scholar
- Leisinger T, Margraff R (1979) Secondary metabolites of the fluorescent pseudomonads. Microbiol Rev 4(3):422–442Google Scholar
- Martin F (1989) Biosynthetic studies on pseudomonic acid. PhD thesis, University of EdinburghGoogle Scholar
- O’Hanlon PJ, Woodford MC, Rogers NH (1980) Isolation of organic acids. United States Patent 4,222,942Google Scholar
- Rubenick JB, Rubim AM, Bellé F, Nogueira-Librelotto DR, Rolim CMB (2017) Preparation of mupirocin-loaded polymeric nanocapsules using essential oil of rosemary Brazilian. J Pharm Sci 53(1):e16101Google Scholar
- Szell V, Lang I, Barta I, Tedges A, Albrecht K, Nee Suto JM, Szabo IM, Petroczki M, Erdei J, Gulyas E, Balogh G (2003) Process for the preparation of pseudomonic acid a antibiotic by microbiological method. US Patent US6506591B2Google Scholar